Get the Stockscreener App
1.18
1.67%
-0.02
After Hours:
1.18
Cytomx Therapeutics Inc stock is traded at $1.18, with a volume of 206.62K.
It is down -1.67% in the last 24 hours and up +0.00% over the past month.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
206.62K
Relative Volume:
0.27
Market Cap:
$94.91M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-1.4048
EPS:
-0.84
Net Cash Flow:
$-56.88M
1W Performance:
+2.61%
1M Performance:
+0.00%
6M Performance:
-45.87%
1Y Performance:
-8.53%
1-Day Range:
$1.18
$1.23
1-Week Range:
$1.13
$1.27
52-Week Range:
$1.04
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
622,616 Shares in ChampionX Co. (NASDAQ:CHX) Bought by Renaissance Technologies LLC - Defense World
Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
CTMX: A Tale of Ups & Downs – -48.46% loss in 6 Months, -5.65% in 30 Days - The InvestChronicle
Insider Selling: Landau Jeffrey B, CytomX Therapeutics Inc [CTMX] Chief Business Officer divested 4,181 shares - Knox Daily
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol, Cytokinetics - Investor's Business Daily
Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex
Analyzing CTMX’s price-to-book ratio for the last quarter - US Post News
Altamira Therapeutics prices up to $12M public offering - MSN
Keeping an Eye on CytomX Therapeutics Inc (CTMX) After Insider Trading Activity - Knox Daily
Check Out CytomX Therapeutics Inc (CTMX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex
HC Wainwright Reaffirms Neutral Rating for CytomX Therapeutics (NASDAQ:CTMX) - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright - MarketBeat
Acadian Asset Management LLC Acquires 37,739 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Candriam S.C.A. Invests $256,000 in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Market Watch Highlights: CytomX Therapeutics Inc (CTMX) Ends on an Upturn Note at 1.31 - The Dwinnex
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can you still get a good price for CytomX Therapeutics Inc (CTMX) Shares at this point? - US Post News
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Taking the lead: CytomX Therapeutics Inc (CTMX) - SETE News
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Becoming More Attractive for Investors - Knox Daily
CTMX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
CytomX Therapeutics Inc [CTMX] Shares Rise 11.61 % on Wednesday - Knox Daily
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
CTMX’s latest rating updates from top analysts. - Knox Daily
Checking in on CytomX Therapeutics Inc (CTMX) after recent insiders movement - Knox Daily
Sean A. Mccarthy Sells 13,898 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock - Defense World
CytomX Therapeutics Inc (CTMX)’s stock chart: A technical perspective - US Post News
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics exec sells over $5k in company stock - Investing.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 13,898 Shares - MarketBeat
CytomX Therapeutics exec sells over $5k in company stock By Investing.com - Investing.com Canada
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):